Search hospitals > Louisiana > Baton Rouge
Louisiana Hematology Oncology Associates LLC
Claim this profileBaton Rouge, Louisiana 70809
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Colorectal Cancer
Conducts research for Non-Small Cell Lung Cancer
88 reported clinical trials
4 medical researchers
Summary
Louisiana Hematology Oncology Associates LLC is a medical facility located in Baton Rouge, Louisiana. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer and other specialties. Louisiana Hematology Oncology Associates LLC is involved with conducting 88 clinical trials across 138 conditions. There are 4 research doctors associated with this hospital, such as David S. Hanson, Victor T. Lin, Augusto C. Ochoa, and William T. Varnado.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
David S. HansonMary Bird Perkins Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
38 reported clinical trials
82 drugs studied
Victor T. LinLouisiana Hematology Oncology Associates LLC9 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
25 reported clinical trials
65 drugs studied
Augusto C. OchoaGulfport Memorial Hospital7 years of reported clinical research
Studies Breast Cancer
Studies Cancer
15 reported clinical trials
69 drugs studied
William T. VarnadoLouisiana Hematology Oncology Associates LLC3 years of reported clinical research
Studies Adenocarcinoma
Studies Pancreatic Cancer
1 reported clinical trial
1 drug studied
Clinical Trials running at Louisiana Hematology Oncology Associates LLC
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Pancreatic Carcinoma
Bladder Cancer
Adenosquamous Carcinoma
ALK Gene Rearrangement
Tumors
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Louisiana Hematology Oncology Associates LLC?
Louisiana Hematology Oncology Associates LLC is a medical facility located in Baton Rouge, Louisiana. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer and other specialties. Louisiana Hematology Oncology Associates LLC is involved with conducting 88 clinical trials across 138 conditions. There are 4 research doctors associated with this hospital, such as David S. Hanson, Victor T. Lin, Augusto C. Ochoa, and William T. Varnado.